Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells

Front Oncol. 2022 Aug 3:12:984514. doi: 10.3389/fonc.2022.984514. eCollection 2022.

Baocheng Gong^{1

2}, Jinhua Zhang¹, Zhongyan Hua^{1

2}, Zhihui Liu³, Carol J Thiele³, Zhijie Li^{1

2}

¹ Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
² Medical Research Center, Liaoning Key Laboratory of Research and Application of Animal Models for Environment and Metabolic Diseases, Shengjing Hospital of China Medical University, Shenyang, China.
³ Cellular and Molecular Biology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

Abstract

[This corrects the article DOI: 10.3389/fonc.2021.686898.].

Keywords: BIM; Bcl-xl; MK-2206; ataxin-3; cisplatin; etoposide; neuroblastoma; perifosine.